Saracco G, Abate M L, Baldi M, Calvo P L, Manzini P, Brunetto M R, Oliveri F, Kuo G, Chien D, Houghton M
Department of Gastroenterology, Molinette Hospital, Turin, Italy.
Liver. 1994 Apr;14(2):65-70. doi: 10.1111/j.1600-0676.1994.tb00049.x.
We measured hepatitis C virus (HCV) RNA and antibodies against HCV recombinant proteins (C22/S1, E1/S2, E2/NS1, C33/NS3, C100/NS4, NS5) in serial serum samples from 22 interferon-treated patients with a long-term follow up (range: 36-44 months). Eleven of them showed persistently normal liver function tests and a significant histological amelioration or a complete resolution of chronic hepatitis (long-term responders, LTRs). In the remaining 11 patients (non-responders (NRs)) liver function tests normalized temporarily during therapy or remained unchanged. At the end of the follow up (3 years), viraemia was undetectable in six of 11 LTRs (54.6%). HCV-RNA was always detectable in the serum of NRs (p = 0.017). At admission, anti-C22/S1, anti-E1/S2, anti-E2/NS1, anti-C33/NS3, anti-C100/NS4 and anti-NS5 were detected in 95.4%, 40.9%, 77.3%, 95.4%, 72.7% and 77.3% of the patients, respectively. Three years after suspension of therapy, anti-C100/NS4 was undetectable in five of six (83.3%) LTRs who cleared HCV-RNA and in only one with ongoing viraemia (20%). Anti-E2/NS1 was undetectable in 54.5% of LTRs and in no NRs (p = 0.067). Anti-E1/S2 was detected more frequently in LTRs than in NRs (81.8% vs 45.5%). Serum levels of anti-C22/S1, C33/NS3 and NS5 did not change during therapy and the follow up in either group of patients. The clearance of viraemia in LTRs was associated with that of anti-C100/NS4 (p = 0.017). Serum HCV-RNA and anti-C100/NS4 appear suitable tools for monitoring patients who respond to therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
我们检测了22例接受干扰素治疗且进行长期随访（36 - 44个月）患者的系列血清样本中的丙型肝炎病毒（HCV）RNA以及针对HCV重组蛋白（C22/S1、E1/S2、E2/NS1、C33/NS3、C100/NS4、NS5）的抗体。其中11例患者肝功能检查持续正常，且慢性肝炎有显著组织学改善或完全缓解（长期应答者，LTRs）。其余11例患者（无应答者（NRs））在治疗期间肝功能检查暂时恢复正常或无变化。随访结束时（3年），11例LTRs中有6例（54.6%）病毒血症检测不到。NRs血清中HCV - RNA始终可检测到（p = 0.017）。入院时，分别有95.4%、40.9%、77.3%、95.4%、72.7%和77.3%的患者检测到抗C22/S1、抗E1/S2、抗E2/NS1、抗C33/NS3、抗C100/NS4和抗NS5。治疗停止3年后，6例清除HCV - RNA的LTRs中有5例（83.3%）抗C100/NS4检测不到，而仅有1例仍有病毒血症的患者抗C100/NS4检测不到（20%）。54.5%的LTRs抗E2/NS1检测不到，而NRs中均未检测到（p = 0.067）。LTRs中抗E1/S2的检测频率高于NRs（81.8%对45.5%）。两组患者在治疗及随访期间抗C22/S1、C33/NS3和NS5的血清水平均无变化。LTRs中病毒血症的清除与抗C100/NS4的清除相关（p = 0.017）。血清HCV - RNA和抗C100/NS4似乎是监测治疗应答患者的合适工具。（摘要截选至250字）
